TY - JOUR
T1 - Mortality in children with optic pathway glioma treated with up-front BB-SFOP chemotherapy
AU - Brain Tumor Committee of SFCE
AU - Rakotonjanahary, Josué
AU - De Carli, Emilie
AU - Delion, Matthieu
AU - Kalifa, Chantal
AU - Grill, Jacques
AU - Doz, François
AU - Leblond, Pierre
AU - Bertozzi, Anne Isabelle
AU - Rialland, Xavier
AU - Alapetite, Claire
AU - André, Nicolas
AU - Bernier, Valérie
AU - Bourdeaut, Franck
AU - Carrié, Christian
AU - Chastagner, Pascal
AU - Conter, Cécile
AU - Dufour, Christelle
AU - Entz-Werlé, Natacha
AU - Branger, Dominique Figarella
AU - Fouyssac, Fanny
AU - Frappaz, Didier
AU - Gentet, Jean Claude
AU - Guichardet, Karien
AU - Habrand, Jean Louis
AU - Hoyoux, Claire
AU - Icher, Céline
AU - Kanold, Justine
AU - Laithier, Véronique
AU - Mosseri, Véronique
AU - Muracciole, Xavier
AU - Padovani, Laetitia
AU - Pagnier, Anne
AU - Palenzuela, Gilles
AU - Perel, Yves
AU - Plantaz, Dominique
AU - Sariban, Eric
AU - Schneider, Pascale
AU - Soler, Christine
AU - Chappé, C.
AU - Sirvent, N.
AU - Berger, C.
AU - Lutz, P.
AU - Blouin, P.
AU - Piguet, C.
AU - Lemoine, P.
AU - Millot, F.
AU - Minckes, O.
AU - Demeocq, F.
AU - De Vathaire, F.
AU - Berardi, E.
N1 - Publisher Copyright:
© 2015 Rakotonjanahary et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2015/6/22
Y1 - 2015/6/22
N2 - Background: In terms of overall survival (OS), limited data are available for the very long-term outcomes of children treated for optic pathway glioma (OPG) with up-front chemotherapy. Therefore, we undertook this study with the aim of clarifying long-term OS and causes of death in these patients. Methods: We initiated and analyzed a historical cohort study of 180 children with OPG treated in France with BB-SFOP chemotherapy between 1990 and 2004. The survival distributions were estimated using Kaplan-Meier method. The effect of potential risk factors on the risk of death was described using Cox regression analysis. Results: The OS was 95% [95% CI: 90.6-97.3] 5 years after diagnosis and significantly decreased over time without ever stabilizing: 91.6%at 10 years [95% CI: 86.5-94.8], 80.7% at 15 years [95% CI: 72.7-86.8] and 75.5% [95% CI: 65.6-83] at 18 years. Tumor progression was the most common cause of death (65%). Age and intracranial hypertension at diagnosis were significantly associated with a worse prognosis. Risk of death was increased by 3.1[95% CI: 1.5-6.2] (p=0.002) for patients less than 1 year old at diagnosis and by 5.2[95% CI: 1.5- 17.6] (p=0.007) for patients with initial intracranial hypertension. Boys without diencephalic syndrome had a better prognosis (HR: 0.3 [95% CI: 0.1-0.8], p=0.007). Conclusions: This study shows that i) in children with OPG, OS is not as favorable as previously described and ii) patients can be classified into 2 groups depending on risk factors (age, intracranial hypertension, sex and diencephalic syndrome) with an OS rate of 50.4% at 18 years [95% CI: 31.4-66.6] in children with the worst prognosis. These findings could justify, depending on the initial risk, a different therapeutic approach to this tumor with more aggressive treatment (especially chemotherapy) in patients with high risk factors.
AB - Background: In terms of overall survival (OS), limited data are available for the very long-term outcomes of children treated for optic pathway glioma (OPG) with up-front chemotherapy. Therefore, we undertook this study with the aim of clarifying long-term OS and causes of death in these patients. Methods: We initiated and analyzed a historical cohort study of 180 children with OPG treated in France with BB-SFOP chemotherapy between 1990 and 2004. The survival distributions were estimated using Kaplan-Meier method. The effect of potential risk factors on the risk of death was described using Cox regression analysis. Results: The OS was 95% [95% CI: 90.6-97.3] 5 years after diagnosis and significantly decreased over time without ever stabilizing: 91.6%at 10 years [95% CI: 86.5-94.8], 80.7% at 15 years [95% CI: 72.7-86.8] and 75.5% [95% CI: 65.6-83] at 18 years. Tumor progression was the most common cause of death (65%). Age and intracranial hypertension at diagnosis were significantly associated with a worse prognosis. Risk of death was increased by 3.1[95% CI: 1.5-6.2] (p=0.002) for patients less than 1 year old at diagnosis and by 5.2[95% CI: 1.5- 17.6] (p=0.007) for patients with initial intracranial hypertension. Boys without diencephalic syndrome had a better prognosis (HR: 0.3 [95% CI: 0.1-0.8], p=0.007). Conclusions: This study shows that i) in children with OPG, OS is not as favorable as previously described and ii) patients can be classified into 2 groups depending on risk factors (age, intracranial hypertension, sex and diencephalic syndrome) with an OS rate of 50.4% at 18 years [95% CI: 31.4-66.6] in children with the worst prognosis. These findings could justify, depending on the initial risk, a different therapeutic approach to this tumor with more aggressive treatment (especially chemotherapy) in patients with high risk factors.
UR - http://www.scopus.com/inward/record.url?scp=84939444523&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0127676
DO - 10.1371/journal.pone.0127676
M3 - Article
C2 - 26098902
AN - SCOPUS:84939444523
SN - 1932-6203
VL - 10
JO - PLoS ONE
JF - PLoS ONE
IS - 6
M1 - e0127676
ER -